Abstract:Objectives Multiple warfarin pharmacogenetic algorithms have been published and been confirmed to predict warfarin dose more accurately than clinical algorithm or fixed-dose approach. However, their performance in Chinese patients has never been evaluated. We sought to compare the performance of published warfarin pharmacogenetic algorithms in a cohort of Chinese patients under warfarin anticoagulation. Methods The study population consisted of 282 unrelated Han-Chinese patients consecutively admitted to the General Hospital of Chinese People9s Liberation Army between January 2008 and July 2011. The patients had all undergone warfarin anticoagulation for various indications and were stably controlled with a target international normalisation ratio (INR) of 1.6–2.5. Genomic DNA extraction from each patient was followed by genotyping to detect the polymorphisms of CYP2C9*3 (rs1057910), VKORC1 −1639 G/A (rs9923231), and CYP4F2*3 (rs2108622) respectively, using standard techniques. A total of 8 eligible pharmacogenetic algorithms were selected for performance comparison. The performance of each algorithm was evaluated by calculating the percentage of patients whose predicted dose fell within 20% of their actual therapeutic dose (percentage within 20%), and the mean absolute error (MAE) between each predicted dose and actual stable dose. Results In the entire cohort, the pharmacogenetic algorithms could predict warfarin dose with the average MAE of 0.87±0.17 mg/day (0.73–1.17 mg/day), and the average percentage within 20% of 43.8%±8.1% (29.1–52.1%). By pair wise comparison, warfarin dose prediction was significantly more accurate with the algorithms derived from Asian patients (48.6–50.0%) than those from Caucasian patients (29.1–39.7%; OR 1.61–3.36, p≤0.02). Algorithms with additional covariates of INR values or CYP4F2*3 performed better than those without the covariates (adding INR: OR: 1.71 (1.08–2.72), p=0.029; adding CYP4F2*3: OR: 2.67 (1.41–5.05), p=0.004). When the patients were stratified according to the dose range, the algorithms from Caucasian and racially mixed populations tended to perform better in higher dose group (≥4.5 mg/day), and algorithms from Asian populations performed better in intermediate dose group (1.5–4.5 mg/day). None of the algorithms performed well in lower dose group (≤1.5 mg/day). Conclusions Our study indicated that none of the eligible pharmacogenetic algorithms could perform the best for all dosing ranges in the present cohort of Chinese patients under warfarin anticoagulation. It may be important to consider the ethnic and clinical specific characteristics when choosing the appropriate algorithm for a local service population. A more refinement pharmacogenetic algorithm combining 3 genotypes (CYP2C9, VKORC1 and CYP4F2) and clinical factors with INR response could potentially improve the warfarin dose prediction in Chinese patients.

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Genetic Polymorphism of CYP2C9 in Patients Receiving Warfarin Anticoagulant Therapy

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

Cyp4f2 Polymorphism As A Genetic Risk Factor for Major Hemorrhagic Complications in Chinese Patients on Warfarin Therapy

System Renew and Meta-Analysis of Effect in Relationship of CYP 2 C9 Genetic Polymorphisms with Warfarin in Chinese Patients

Identification and Functional Assessment of Eight CYP3A4 Allelic Variants 39-46 Detected in the Chinese Han Population

Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C972-75 in the Chinese Han population

Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient

Comparative Performance of Gene-Based Warfarin Dosing Algorithms in Chinese Patients

Effects of CYP2C9 and VKORC1 Genetic Polymorphisms in Chinese Han Population on Maintenance Dosage of Warfarin

Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.

The correlation of the Warfarin drug sensitivity with CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation